MAPT and early-onset autosomal dominant Alzheimer disease: The monoclonal antibody AT180 that specifically recognizes tau phosphorylation at the T231 site is currently used to define an Alzheimer’s disease (AD)-related pathological form of the phosphorylated tau protein [22].